2seventy bio, Inc. Sustainability Profile
2seventy bio, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing transformative cell therapies for cancer treatment. Founded in 2020, the company has quickly established itself in the biopharmaceutical industry, particularly in the areas of engineered cell therapies and innovative drug development. With a commitment to advancing the field of oncology, 2seventy bio's core offerings include cutting-edge therapies that harness the power of the immune system to target and eliminate cancer cells. Their unique approach combines scientific expertise with a patient-centric focus, setting them apart in a competitive market. Recognised for its rapid progress and innovative solutions, 2seventy bio is positioned as a leader in the fight against cancer, striving to improve patient outcomes and redefine treatment paradigms.
DitchCarbon Score
How does 2seventy bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
2seventy bio, Inc.'s score of 69 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
2seventy bio, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Bristol-Myers Squibb Company, which influences its climate commitments and emissions reporting. As part of its corporate family, 2seventy bio, Inc. inherits climate initiatives and targets from Bristol-Myers Squibb. This includes commitments to the Science Based Targets initiative (SBTi) and other sustainability frameworks. However, specific reduction targets or achievements for 2seventy bio, Inc. have not been disclosed. The absence of direct emissions data suggests that 2seventy bio, Inc. is in the process of establishing its own climate strategy, potentially aligning with the broader goals set by its parent company. The company is expected to contribute to the overarching sustainability efforts of Bristol-Myers Squibb, which may include significant reductions in Scope 1, 2, and 3 emissions as part of their corporate responsibility initiatives. In summary, while 2seventy bio, Inc. does not currently report specific emissions figures or reduction targets, it is positioned within a framework of climate commitments inherited from Bristol-Myers Squibb, indicating a commitment to sustainability and emissions reduction in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is 2seventy bio, Inc.'s Industry?
How Carbon Intensive is 2seventy bio, Inc.'s Location?
2seventy bio, Inc.'s Scope 3 Categories Breakdown
2seventy bio, Inc.'s Scope 3 emissions, which decreased by 1% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Top Scope 3 Categories
2seventy bio, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
2seventy bio, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
